Cis-acting interferon based A-Kine therapeutic / Orionis - LARVOL DELTA

Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer (Businesswire) - "Orionis Biosciences...presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16 in Barcelona, Spain. The data demonstrate potent anti-tumor activity across multiple classes of targeted cytokines....The company presented its advances and breakthroughs in design, engineering and development of exquisitely target-selective A-Kines incorporating: Cis-acting Interferons to promote immune system recognition and infiltration of tumors; Cis-acting Interleukin-2 to directly activate CD8+ tumor cytotoxic T cells."

Preclinical • Oncology